IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION

STEPHANIE DENISE BARNETT AND KEVIN CRAWFORD,) Civil Action No.:)
Plaintiffs,) Judge:
V.	
BAYER HEALTHCARE PHARMACEUTICALS INC.,) COMPLAINT WITH JURY DEMAND
Defendant.)

Plaintiffs Stephanie Barnett and Kevin Crawford ("Plaintiffs"), by and through the undersigned attorneys, hereby bring this cause of action for personal injuries suffered as a proximate result of Plaintiff Stephanie Barnett being prescribed and using the defective and unreasonably dangerous product Mirena® (levonorgestrel-releasing intrauterine system). At all times relevant hereto, Mirena® was manufactured, designed, formulated, tested, packaged, labeled, produced, created, made, constructed, assembled, marketed, advertised, distributed and sold by Bayer Healthcare Pharmaceuticals, Inc. ("Bayer").

PARTIES AND CITIZENSHIP

1. At all relevant times hereto, Plaintiffs Stephanie Barnett and Kevin Crawford were residents and citizens of Cleveland, Ohio.

2. Defendant Bayer Healthcare Pharmaceuticals Inc., is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 6 West

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 2 of 12. PageID #: 2

Belt Road, Wayne, New Jersey 07470. Defendant Bayer Healthcare Pharmaceuticals, Inc., can be served with process through its registered agent for service of process in Ohio, Corporation Service Company, 50 West Broad St., Suite 1800, Columbus, Ohio 43215.

3. Defendant Bayer Healthcare Pharmaceuticals, Inc. was formerly known as Berlex, Inc., which was formerly known as Berlex Laboratories, Inc.

4. Berlex Laboratories, Inc. and Berlex, Inc. were integrated into Bayer HealthCare AG and operate as an integrated specialty pharmaceuticals business under the new name, Defendant Bayer Healthcare Pharmaceuticals, Inc.

5. Defendant Bayer Healthcare Pharmaceuticals Inc. is the holder of the approved New Drug Application (NDA) for contraceptive device Mirena®.

6. Bayer is in the business of designing, manufacturing, marketing, formulating, testing, packaging, labeling, producing, creating, making, constructing, assembling, advertising, and distributing prescription drugs and women's healthcare products, including the intrauterine contraceptive system, Mirena®.

7. Bayer does business in Ohio through the sale of Mirena® and other prescription drugs in the state.

8. At all times relevant, Defendant was engaged in the business of developing, designing, licensing, manufacturing, distributing, selling, marketing, and/or introducing into interstate commerce throughout the United States, either directly or indirectly through third parties, subsidiaries or related entities, the contraceptive device, Mirena®.

JURISDICTION AND VENUE

9. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332, because the amount in controversy as to the Plaintiff exceeds \$75,000.00, exclusive of interest and costs,

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 3 of 12. PageID #: 3

and because Defendant is incorporated and has its principal places of business in states other than the state in which the named Plaintiff resides.

10. This Court has supplemental jurisdiction over the remaining common law and state claims pursuant to 28 U.S.C. § 1367.

11. Venue is proper in this Court pursuant to 28 U.S.C. § 1391 because a substantial part of the events giving rise to Plaintiffs' claims occurred, in part, in the Northern District of Ohio, Eastern Division.

FACTS

12. Plaintiffs incorporate by reference all other paragraphs of this complaint as if fully set forth herein, and further allege as follows:

13. Mirena® is an intrauterine system that is inserted by a healthcare provider during an office visit. Mirena® is a T-shaped polyethylene frame with a steroid reservoir that releases $20 \mu g/day$ of levonorgestrel, a prescription medication used as a contraceptive.

14. The federal Food and Drug Administration (FDA) approved Defendants' New Drug Application for Mirena® in December 2000. Today, more than 2 million women in the United States use Mirena®. It has been used by more than 15 million women worldwide.

15. The system releases levonorgestrel, a synthetic progestogen, directly into the uterus for birth control. Defendants admit "i]t is not known exactly how Mirena works," but provide that Mirena® may thicken cervical mucus, thin the uterine lining, inhibit sperm movement and reduce sperm survival to prevent pregnancy.

16. The Mirena® intrauterine system ("IUS") is designed to be placed within seven(7) days of the first day of menstruation and is approved to remain in the uterus for up to five (5)

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 4 of 12. PageID #: 4

years. If continued use is desired after five years, the old system must be discarded and a new one inserted.

17. The package labeling recommends that Mirena® be used in women who have had at least one child.

18. Mirena®' s label does not warn about spontaneous migration of the IUS, but only states that migration may occur if the uterus is perforated during insertion.

19. Mirena®'s label also describes perforation as an "uncommon" event, despite the numerous women who have suffered migration and perforation post-insertion, clearly demonstrating this assertion to be false.

20. Defendant has a history of overstating the efficacy of Mirena® while understating the potential safety concerns.

21. In or around December 2009, Defendant was contacted by the Department of Health and Human Services' Division of Drug Marketing, Advertising, and Communications (DDMAC) regarding a consumer-directed program entitled "Mirena Simple Style Statements Program," a live presentation designed for "busy moms." The Simple Style program was presented in a consumer's home or other private setting by a representative from "Mom Central", a social networking internet site, and Ms. Barb Dehn, a nurse practitioner, in partnership with Defendants.

22. This Simple Style program represented that Mirena® use would increase the level of intimacy, romance and emotional satisfaction between sexual partners. DDMAC determined these claims were unsubstantiated and, in fact, pointed out that Mirena®' s package insert states that at least 5% of clinical trial patients reported a decreased libido after use.

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 5 of 12. PageID #: 5

23. The Simple Style program script also intimated that Mirena® use can help patients "look and feel great." Again, DDMAC noted these claims were unsubstantiated and that Mirena® can cause a number of side effects, including weight gain, acne, and breast pain or tenderness.

24. The portion of the Simple Style script regarding risks omitted information about serious conditions, including susceptibility to infections and the possibility of miscarriage is a woman becomes pregnant on Mirena®.

25. Finally, Defendant falsely claimed that Defendant's product required no compliance with a monthly routine.

26. Plaintiff Stephanie Barnett is currently 45 years old.

27. Plaintiff had the Mirena® IUS inserted in 2008, by Lakewood Midwifery in Lakewood, Ohio. While she suffered some mild discomfort and bleeding, the insertion was uncomplicated.

28. On or about September 12, 2012, as the result of vaginal bleeding, Plaintiff underwent a pelvic ultrasound and a transvaginal ultrasound at Lakewood Hospital. The radiologist was unable to visualize the Mirena IUD within Plaintiff's uterus.

29. In October, 2012, Plaintiff received an abdominal x-ray at MetroHealth Medical Center, which demonstrated that the Mirena was outside of her uterus and within her abdomen.

30. Plaintiff is scheduled to undergo a laparoscopy under general anesthesia on November 28, 2012 at MetroHealth Medical Center.

31. This procedure carries with it risks, such as adverse reaction to anesthesia, infection, perforation of other organs, and adhesion formation, to name a few.

FIRST CAUSE OF ACTION PRODUCT DEFECT IN DESIGN OR FORMULATION OHIO REVISED CODE § 2307.75

32. Plaintiffs repeat, reiterate, and reallege each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

33. At all times herein mentioned, Defendant manufactured, designed, formulated, produced, created, made, constructed and/or assembled Mirena®, used by Plaintiff.

34. Defendant's Mirena® was defective in that at the time Mirena® left the control of Defendant, the foreseeable risks associated with its design or formulation exceeded the benefits associated with that design or formulation.

35. Mirena® was in an unsafe, defective, and inherently dangerous condition which was unreasonably dangerous to its users and, in particular, Plaintiff.

36. At all times herein mentioned, Mirena® was in a defective condition and unsafe, and Defendant knew, had reason to know, or should have known that said Mirena® was defective and unsafe, especially when used as instructed and in the form and manner as provided by Defendant.

37. The nature and magnitude of the risk of harm associated with the design and formulation of Mirena®, including uterine migration and perforation, is high in light of the intended and reasonably foreseeable use of Mirena® as a reversible form of contraceptive.

38. It is highly unlikely that Mirena® users would be aware of the risks associated with Mirena® through either warnings, general knowledge or otherwise. Plaintiff was not aware of said risks.

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 7 of 12. PageID #: 7

39. The likelihood was high that the design or formulation would cause the harm of uterine migration and perforation, in light of the intended and reasonably foreseeable use of Mirena® as a reversible form of contraceptive.

40. The design or formulation did not conform to any applicable public or private product standard that was in effect when Mirena® left the control of its manufacturer, the Defendant.

41. The design or formulation of Mirena® is more dangerous than a reasonably prudent consumer would expect when used in the intended or reasonable foreseeable manner as a reversible form of contraceptive. It was more dangerous than Plaintiff expected.

42. The intended or actual utility of Mirena® is not of such benefit to justify the risk of uterine migration, perforation and even infertility.

43. There was both technical and economic feasibility, at the time Mirena® left Defendants' control, of using an alternative design or formulation that would not cause uterine migration or perforation.

44. The defective design or formulation of Mirena® was not caused by an inherent characteristic of the Mirena® which is a generic aspect of all contraceptive medications that cannot be eliminated without substantially compromising Mirena®' usefulness or desirability and which is recognized by the ordinary person. This is demonstrated by numerous safer alternative therapies that are available on the market to prevent contraception, without the harmful side effects that can result from Mirena® use.

45. A practical and technically feasible alternative design or formulation was available that would have prevented the harm for which Plaintiff suffered.

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 8 of 12. PageID #: 8

46. By reason of the foregoing, the Defendant is liable to the Plaintiff for the manufacturing, designing, formulating, producing, creating, making, constructing, and/or assembling a product that is defective in design and formulation.

SECOND CAUSE OF ACTION PRODUCT DEFECT DUE TO INADEQUATE WARNING AND/OR INSTRUCTION OHIO REVISED CODE § 2307.76

47. Plaintiffs repeat, reiterate, and reallege each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

48. Defendant had a duty to warn Plaintiff of the risks associated with Mirena®, namely, the risk of spontaneous migration and uterine perforation.

49. Defendants knew, or in the exercise or reasonable care, should have known about the risk of spontaneous migration and uterine perforation.

50. Defendants failed to provide warnings or instructions that a manufacturer exercising reasonable care would have provided concerning the risk of spontaneous migration and uterine perforation, in light of the likelihood that their product would cause spontaneous migration and uterine perforation, for which Plaintiff suffered.

51. Defendants' Mirena® is defective due to inadequate post-marketing warning or instruction.

52. Defendants knew, or in the exercise or reasonable care, should have known about the risk that their Mirena® causes spontaneous migration and uterine perforation.

53. Defendants failed to provide post-marketing warnings or instructions that a manufacturer exercising reasonable care would have provided concerning the risk of

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 9 of 12. PageID #: 9

spontaneous migration and uterine perforation, in light of the likelihood that the product causes spontaneous migration and uterine perforation, for which Plaintiff suffered.

54. Defendants' product does not contain a warning or instruction regarding spontaneous migration and uterine perforation for normal healthy individuals.

55. The risk of spontaneous migration and uterine perforation is not an open and obvious risk or a risk that is a matter of common knowledge in regards to Mirena®.

56. By reason of the foregoing, the Defendant is liable to the Plaintiff, for the manufacturing, designing, formulating, producing, creating, making, constructing, and/or assembling a product that is defective due to inadequate warning or instruction.

THIRD CAUSE OF ACTION PRODUCT DEFECT IN FAILURE TO CONFORM TO REPRESENTATIONS OHIO REVISED CODE § 2307.77

57. Plaintiffs repeat, reiterate, and reallege each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

58. Plaintiff repeats, reiterates, and realleges each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

59. The Defendant's product was defective in that, when it left the control of Defendant, the product did not conform to representations made by Defendant.

60. Said representations are false, misleading, and inaccurate.

61. Defendant describes and represents that their product has characteristics that simply do not conform to reality. Rather than acknowledging that Defendant's product causes spontaneous migration and uterine perforation, Defendants describe Mirena® as being safe.

Case: 1:12-cv-02780 Doc #: 1 Filed: 11/07/12 10 of 12. PageID #: 10

62. These representations are in stark contrast to the spontaneous migration and uterine perforation that Mirena® does actually cause.

63. While Plaintiff believes and avers that Defendant acted negligently and recklessly in making the representations, in the event Defendant is not found to have acted negligently or recklessly, Defendant is still liable for the damages and injuries suffered by Plaintiff pursuant to ORC § 2307.77.

64. By reason of the foregoing, the Defendant is liable to the Plaintiff for the manufacturing, designing, formulating, producing, creating, making, constructing, and/or assembling a product that is defective in that it did not conform, at the time it left the control of Defendant, to representations made by Defendant.

FOURTH CAUSE OF ACTION PUNATIVE DAMAGES OHIO REVISED CODE § 2307.80

65. Plaintiffs repeat, reiterate, and reallege each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

66. Plaintiff's injury was the result of misconduct of Defendant that manifested a flagrant disregard of the safety of persons who might be harmed by the product in question.

67. Defendant fraudulently and in violation of applicable regulations of the FDA withheld from the FDA information known to be material and relevant to the harm that the Plaintiff suffered or misrepresented to the FDA information of that type.

68. By reason of the foregoing, the Defendant is liable to the Plaintiff for punitive damages, for the manufacturing, designing, formulating, producing, creating, making, constructing, and/or assembling a product that is defective under the Ohio Product Liability Act.

FIFTH CAUSE OF ACTION LOSS OF CONSORTIUM

69. Plaintiffs repeat, reiterate, and reallege each and every allegation of this Complaint in each of the foregoing paragraphs inclusive, with the same force and effect as if fully set forth herein.

70. Plaintiff Kevin Crawford is the husband of Stephanie Barnett.

71. As a result of the medical conditions developed by his wife and the medical treatment and hospitalization that she has and will endure, Plaintiff Kevin Crawford:

a. lost a substantial measure of his wife's household services; and

b. lost, and will continue to lose in the future, a substantial measure of his wife's consortium.

72. As a direct and proximate result of one or more of these wrongful acts or omissions of the Defendant, Plaintiff Kevin Crawford suffered injuries.

WHEREFORE, Plaintiffs demand judgment against Defendant for compensatory, statutory and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as the Court deems appropriate pursuant to the common law and statutory law

PRAYER FOR RELIEF

Plaintiffs demand judgment against Defendant for compensatory, statutory and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as the Court deems appropriate pursuant to the common law and statutory law.

JURY DEMAND

A jury trial is requested.

Dated: November 7, 2012

Respectfully submitted,

s/ Dawn M. Chmielewski John R. Climaco (OH # 0011456) jrclim@climacolaw.com Dawn M. Chmielewski (OH #0077723) dxchmi@climacolaw.com Margaret M. Metzinger (OH#0065624) mmmetz@climacolaw.com CLIMACO, WILCOX, PECA, TARANTINO & GAROFOLI CO., LPA 55 Public Square, Suite 1950 Cleveland, Ohio 44113 Telephone: (216) 621-8484 Facsimile: (216) 771-1632

Counsel for Plaintiff Stephanie Barnett and Kevin Crawford

Case: 1:12-cv-02780 Dec #:1-1 Electric 11/07/12 1 of 3. PageID #: 13

JS 44 (Rev. 10/4/11)

The JS 44 civil coversheet and the information contained herein neither replace nor supplement the filing and service of pleadngs or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States inSeptember 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. *(SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)*

I. (a) PLAINTIFFS STEPHANIE DENISE BARNETT AND KEVIN CRAWFORD			DEFENDANTS BAYER HEALTHCARE PHARMACEUTICALS INC.			
(b) County of Residence of First Listed Plaintiff <u>Cuyahoga</u> (EXCEPT IN U.S. PLAINTIFF CASES)			County of Residence of First Listed Defendant (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.			
(c) Attorneys (Firm Name, awn M. Chmielewski, Clin LPA, 55 Public Square, S						
II. BASIS OF JURISD	ICTION (Place an "X" is	n One Box Only)	III. CITIZENSHIP OF P	RINCIPAL PARTIES		
□ 1 U.S. Government Plaintiff	 Federal Question (U.S. Government Not a Party) 		(For Diversity Cases Only) and One Box for Defendant) PTF DEF PTF DEF Citizen of This State Image: Compared on Principal Place Image: Compared on Principal Place Image: Compared on Principal Place Of Business In This State Image: Compared on Principal Place Image: Compared on Principal Place Image: Compared on Place			
□ 2 U.S. Government Defendant	X 4 Diversity (Indicate Citizenship of Parties in Item III)			of Business In Another State		
			Citizen or Subject of a Foreign Country	3 3 Foreign Nation		
IV. NATURE OF SUIT						
CONTRACT 110 Insurance 120 Marine 130 Miller Act 140 Negotiable Instrument 150 Recovery of Overpayment & Enforcement of Judgment 151 Medicare Act 152 Recovery of Defaulted Student Loans (Excl. Veterans) 153 Recovery of Overpayment of Veteran's Benefits 160 Stockholders' Suits 190 Other Contract 195 Contract Product Liability 196 Franchise REAL PROPERTY 210 Land Condemnation 220 Foreclosure 230 Rent Lease & Ejectment 240 Torts to Land 245 Tort Product Liability 290 All Other Real Property	TO PERSONAL INJURY □ 310 Airplane □ 315 Airplane Product Liability □ 320 Assault, Libel &	 RTS PERSONAL INJUR □ 365 Personal Injury - Product Liability 367 Health Care/ Pharmaceutical Personal Injury Product Liability □ 368 Asbestos Persona Injury Product Liability 	of Property 21 USC 881 General General Conter Conternal	BANKRUPTCY 422 Appeal 28 USC 158 423 Withdrawal 28 USC 157 PROPERTY RIGHTS 820 Copyrights 830 Patent 840 Trademark SOCIAL SECURITY 861 HIA (1395ff) 862 Black Lung (923) 863 DIWC/DIWW (405(g)) 865 RSI (405(g)) FEDERAL TAX SUITS 870 Taxes (U.S. Plaintiff or Defendant) 871 IRS—Third Party 26 USC 7609	OTHER STATUTES 375 False Claims Act 400 State Reapportionment 410 Antitrust 430 Banks and Banking 450 Commerce 460 Deportation 470 Racketeer Influenced and Corrupt Organizations 480 Consumer Credit 490 Cable/Sat TV 850 Securities/Commodities/ Exchange 890 Other Statutory Actions 891 Agricultural Acts 895 Freedom of Information Act 896 Arbitration 899 Administrative Procedure Act/Review or Appeal of Agency Decision 950 Constitutionality of State Statutes	
IZI Original □ 2 Re	n "X" in One Box Only) moved from 3 1 te Court	Remanded from		ferred from \Box 6 Multidistr r district $Litigation$		
VI. CAUSE OF ACTION	DN 28 U.S.C. § 1332 Brief description of ca	2 use:	re filing (Do not cite jurisdictional sta			
VII. REQUESTED IN	_	acturing/Products L IS A CLASS ACTION	iability, Loss of Consortium DEMAND \$	CHECK YES only	if demanded in complaint:	
COMPLAINT:	UNDER F.R.C.P.			JURY DEMAND:	Ves 🗆 No	
VIII. RELATED CASI IF ANY	E(S) (See instructions):	JUDGE		DOCKET NUMBER		
DATE			TORNEY OF RECORD			
11/07/2012 FOR OFFICE USE ONLY		s/ Dawn M. Ch	mielewski			
	MOUNT	APPLYING IFP	JUDGE	MAG. JUI)GE	
RECEIF I # AN		ATTL HING IFP	JUDGE	MAG. JUL		

Case: 1:12-cv-02780 Doc #: 1-1 Filed: 11/07/12 2 of 3. PageID #: 14 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO

Civil Categories: (Please check one category only).



3.

I.

General Civil Administrative Review/Social Security

Habeas Corpus Death Penalty

*If under Title 28, §2255, name the SENTENCING JUDGE:

CASE NUMBER:

II. <u>RELATED OR REFILED CASES</u>. See LR 3.1 which provides in pertinent part: "If an action is filed or removed to this Court and assigned to a District Judge after which it is discontinued, dismissed or remanded to a State court, and subsequently refiled, it shall be assigned to the same Judge who received the initial case assignment without regardfor the place of holding court in which the case was refiled. Counsel or a party without counsel shall be responsible for bringing such cases to the attention of the Court by responding to the questions included on the Civil Cover Sheet."

This action is **RELATED** to another **PENDING** civil case. This action is **REFILED** pursuant to LR 3.1.

If applicable, please indicate on page 1 in section VIII, the name of the Judge and case number.

III. In accordance with Local Civil Rule **3.8**, actions involving counties in the Eastern Division shall be filed at any of the divisional offices therein. Actions involving counties in the Western Division shall be filed at the Toledo office. For the purpose of determining the proper division, and for statistical reasons, the following information is requested.

ANSWER ONE PARAGRAPH ONLY. ANSWER PARAGRAPHS 1 THRU 3 IN ORDER. UPON FINDING WHICH PARAGRAPH APPLIES TO YOUR CASE, ANSWER IT AND STOP.

(1) **<u>Resident defendant</u>**. If the defendant resides in a county within this district, please set forth the name of such county

COUNTY:

<u>Corporation</u> For the purpose of answering the above, a corporation is deemed to be a resident of that county in which it has its principal place of business in that district.

- (2) <u>Non-Resident defendant</u>. If no defendant is a resident of a county in this district, please set forth the county wherein the cause of action arose or the event complained of occurred.
- COUNTY:
- (3) <u>Other Cases</u>. If no defendant is a resident of this district, or if the defendant is a corporation not having a principle place of business within the district, and the cause of action arose or the event complained of occurred outside this district, please set forth the county of the plaintiff's residence.

COUNTY:

IV. The Counties in the Northern District of Ohio are divided into divisions as shown below. After the county is determined in Section **III**, please check the appropriate division.

EASTERN DIVISION

CLEVELAND
YOUNGSTOWN

(Counties: Carroll, Holmes, Portage, Stark, Summit, Tuscarawas and Wayne) (Counties: Ashland, Ashtabula, Crawford, Cuyahoga, Geauga, Lake, Lorain, Medina and Richland) (Counties: Columbiana, Mahoning and Trumbull)

WESTERN DIVISION



(Counties: Allen, Auglaize, Defiance, Erie, Fulton, Hancock, Hardin, Henry, Huron, Lucas, Marion, Mercer, Ottawa, Paulding, Putnam, Sandusky, Seneca VanWert, Williams, Wood and Wyandot)

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

I. (a) Plaintiffs-Defendants. Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.

(b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)

(c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".

II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.C.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.

United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.

United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdicti on arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is aparty, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; federal question actions take precedence over diversity cases.)

III. Residence (citizenship) of Principal Parties. This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.

IV. Nature of Suit. Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerks in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.

V. Origin. Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.

Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.

Appeal to District Judge from Magistrate Judgment. (7) Check this box for an appeal from a magistrate judge's decision.

VI.Cause of Action.Report the civil statute directly related to the cause of action and give a brief description of the cause Do not cite jurisdictional statutesunless diversity.Example:U.S. Civil Statute: 47 USC 553
Brief Description: Unauthorized reception of cable service

VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.

Demand. In this space enter the dollar amount (in thousands of dollars) being demanded or indicate other demand such as a preliminary injunction.

Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.

VIII. Related Cases. This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.

Case: 1:12-cv-02780 Doc #: 1-2 Filed: 11/07/12 1 of 2. PageID #: 16

AO 440 (Rev. 12/09) Summons in a Civil Action

UNITED STATES DISTRICT COURT

for the

Northern District of Ohio

)

)

))

)

)

STEPHANIE DENISE BARNETT AND KEVIN

CRAWFORD Plaintiff

v.

BAYER HEALTHCARE PHARMACEUTICALS INC.

Defendant

Civil Action No. 1:12-cv-2780

SUMMONS IN A CIVIL ACTION

To: (Defendant's name and address)

Bayer Healthcare Pharmaceuticals, Inc. c/o Corporation Service Company 50 West Broad St., Suite 1800 Columbus, Ohio 43215

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

Dawn M. Chmielewski, Esq. Climaco, Wilcox, Peca, Tarantino & Garofoli Co., LPA 55 Public Square, Suite 1950 Cleveland, Ohio 44113

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Case: 1:12-cv-02780 Doc #: 1-2 Filed: 11/07/12 2 of 2. PageID #: 17

AO 440 (Rev. 12/09) Summons in a Civil Action (Page 2)

Civil Action No. 1:12-cv-2780

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

	This summons for (n	ame of individual and title,	if any)					
was rec	ceived by me on (date)							
	□ I personally serve	ed the summons on the	individual at (place)					
	on (<i>date</i>); o			; or	or			
	□ I left the summon	s at the individual's re-	-	ce of abode with (name)				
	, a person of suitable age and discretion who resides there,							
	on (date), and mailed a copy to the individual's last known address; or							
	□ I served the summons on (<i>name of individual</i>)							
	designated by law to	accept service of proc						
	on (date) ;							
	□ I returned the summons unexecuted because					; or		
	Other (<i>specify</i>):							
			1.0					
	My fees are \$	for travel a	nd \$	for services, for a total of \$	0.0			
	I declare under pena	lty of perjury that this i	information is true.					
Date:								
Date.		<u>.</u> .		Server's signature				
				Printed name and title				

Server's address

Additional information regarding attempted service, etc: